I saw this post and wanted to ask the opposite. What are some items that really aren’t worth paying the expensive version for? Preferably more extreme or unexpected examples.
Not exactly. Just a fun fact and disclaimer that I use generics if at all possible. But my pharmacology class taught that generics can have higher tolerance of error in % of active ingredient. Not usually a big deal unless the drug has a very narrow therapeutic range, meaning too little doesn’t work and too much will harm you. 99.9% of generics is fine. But if you ever wonder if one batch of your med doesn’t seem to work as well this it’s likely that batch was on the lower end of acceptable.
I think this depends where you live, having worked a summer as a trolley runner for blister pack production, we produced thousands of blisters, and at the end of the line half got pharmacy own brand foils and the other half got name brand foils.
Same pills, same packs, same factory same standards and testing, just different ink on the foils. But the pharmacy brands would have shorter contracts so they would only be identical to this name brand for 6 months, then try might get a contract with another factory and be identical to another name brand there.
I know with some drugs (Warfarin is the only one that’s instantly coming to mind) it is important to pick a brand and stick with it because the slightest change can effect the therapeutic value.
For myself, I have allergies so sometimes a certain brand or manufacturing company will use a filler, binder or dye I can’t have. And frustratingly there are no ingredients lists on pills for fillers and dyes.
That’s true but the difference is exceedingly small.
According to 1 FDA study, the mean difference for AUC values between test and reference products was found to be 3.5% in the 2-year period following the Waxman-Hatch Act, and 80% of the absolute differences between generic products approved since 1984 and the corresponding innovator products were within a 5% range.
Debunking a Common Pharmacy Myth: The 80-125% Bioequivalence Rule Jun 8, 2016
